Compare MFA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | GERN |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 911.0M |
| IPO Year | 1998 | 1996 |
| Metric | MFA | GERN |
|---|---|---|
| Price | $9.15 | $1.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $11.05 | $2.17 |
| AVG Volume (30 Days) | 1.5M | ★ 10.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 14.16% | N/A |
| EPS Growth | ★ 58.54 | 51.85 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $10.02 | $43.75 |
| P/E Ratio | $39.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.80 | $1.04 |
| 52 Week High | $10.57 | $2.01 |
| Indicator | MFA | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 58.78 |
| Support Level | $8.90 | $1.42 |
| Resistance Level | $9.38 | $1.69 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 67.37 | 84.88 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.